Biocon Limited has announced the issuance of Commercial Papers worth ₹200 crores on a private placement basis, as disclosed to the stock exchanges on January 2, 2026. The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Commercial Paper Details

The commercial papers carry attractive terms for short-term funding requirements. The key parameters of the issuance are structured as follows:

Listing and Investor Details

The commercial papers are proposed to be listed on the National Stock Exchange of India Limited, providing liquidity options for investors. The entire issue has been allocated to institutional investors, specifically:

• Kotak Mahindra Trustee Company Ltd A/C Kotak Low Duration Fund
• Kotak Mahindra Trustee Company Ltd A/C Kotak Floating Rate Fund

The payment schedule for both coupon interest and principal repayment is set for March 3, 2026, aligning with the maturity date of the instruments.

Regulatory Compliance

The issuance follows standard regulatory protocols with no special rights, interests, or privileges attached to the instruments. Biocon has confirmed that no charges or security have been created over the company's assets for this commercial paper issuance. The company has also stated that there are no delays in payment or defaults concerning previous instruments, maintaining its clean payment track record.

This commercial paper issuance represents a standard short-term funding mechanism for the pharmaceutical company, providing working capital flexibility while offering institutional investors a rated short-term investment opportunity. The information regarding this issuance is also available on the company's official website for stakeholder reference.

Biocon Limited has issued commercial papers worth ₹1,800 crores on private placement basis, as disclosed in its regulatory filing dated December 22, 2025. The pharmaceutical company has now declared the record date for the maturity of these commercial papers, with the debt instrument carrying a coupon rate of 6.85% and scheduled to mature on March 20, 2026.

Record Date Declaration

In a regulatory filing dated December 24, 2025, Biocon Limited has intimated the stock exchanges about the record date for its commercial paper maturity. The company has set March 19, 2026 as the record date, one day prior to the maturity date.

Commercial Paper Issuance Details

The key parameters of Biocon's commercial paper issuance are outlined below:

Investor Base

The commercial papers have been allotted to prominent mutual fund houses, demonstrating institutional confidence in Biocon's creditworthiness:

Strategic Capital Management

The ₹1,800 crore commercial paper issuance represents Biocon's strategic approach to short-term funding requirements. With a tenure of approximately three months and competitive interest rate of 6.85%, the instrument provides cost-effective financing for the company's operational needs.

The unsecured nature of the commercial papers, coupled with the IND A1+ credit rating, reflects the company's strong financial standing and market credibility. The participation of leading mutual fund houses further validates the investment quality of Biocon's debt instruments, while the formal record date declaration ensures proper settlement procedures for the maturing instrument.